🇺🇸 LLY — Eli Lilly and Company

Healthcare Compra
← Volver

Precio actual

1.149,36 USD

Máx. histórico

1.292,65

16 días

Caída desde máximo

-11,08%

Rango 52 semanas

712,05 – 1.292,65

Variación hoy

-0,88%

Cierre anterior

1.159,60

Rango de hoy

1.138,31 – 1.158,43

Volumen hoy

2.159.931

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
50.000
PER
38,91 (puede no estar actualizado)
Dividend yield
0,60% (puede no estar actualizado)
Precio objetivo analistas
1.315,56 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 2 días
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,58%
Fecha de pago Importe por participación
03/11/1977 0,0222 USD
08/08/1977 0,0222 USD
09/05/1977 0,0222 USD
04/02/1977 0,0222 USD
05/11/1976 0,0203 USD
09/08/1976 0,0203 USD
10/05/1976 0,0188 USD
06/02/1976 0,0188 USD
07/11/1975 0,0172 USD
11/08/1975 0,0172 USD
12/05/1975 0,0172 USD
07/02/1975 0,0172 USD
08/11/1974 0,0156 USD
12/08/1974 0,0156 USD
13/05/1974 0,0147 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/03/2017 84,40 84,94 84,08 84,11 -0,77% 1,02% 3.151.900
30/03/2017 84,57 84,95 84,08 84,76 +0,38% 1,03% 3.204.100
29/03/2017 84,55 84,76 84,32 84,44 -0,37% 0,52% 2.066.600
28/03/2017 84,27 85,00 84,04 84,75 +0,61% 1,14% 2.755.000
27/03/2017 83,90 84,44 83,74 84,24 +0,07% 0,83% 2.340.300
24/03/2017 84,30 84,98 83,86 84,18 -0,28% 1,33% 2.479.100
23/03/2017 83,92 85,05 83,92 84,42 +0,07% 1,35% 3.021.100
22/03/2017 84,09 84,55 83,47 84,36 +0,75% 1,28% 2.850.300
21/03/2017 84,34 84,95 83,63 83,73 -0,39% 1,57% 4.066.200
20/03/2017 84,60 84,86 83,97 84,06 +0,12% 1,05% 3.121.900
17/03/2017 84,44 84,75 83,83 83,96 -1,21% 1,09% 5.786.900
16/03/2017 85,54 85,54 83,80 84,99 -1,04% 2,03% 4.742.800
15/03/2017 84,43 86,14 84,37 85,88 +1,68% 2,10% 4.883.900
14/03/2017 84,00 84,55 83,92 84,46 +0,38% 0,75% 2.839.100
13/03/2017 84,51 84,55 83,83 84,14 -0,26% 0,85% 2.248.500
10/03/2017 84,50 84,55 83,90 84,36 -0,22% 0,77% 3.629.400
09/03/2017 83,67 84,77 83,51 84,55 +1,37% 1,51% 5.861.600
08/03/2017 82,74 83,99 82,67 83,41 +0,81% 1,60% 4.491.800
07/03/2017 82,95 83,14 81,37 82,74 -1,30% 2,13% 5.570.600
06/03/2017 83,25 84,28 82,95 83,83 +0,06% 1,60% 3.960.100
03/03/2017 82,70 83,90 82,60 83,78 +1,05% 1,57% 2.649.100
02/03/2017 83,87 83,95 82,84 82,91 -1,12% 1,32% 3.371.600
01/03/2017 83,44 84,14 82,97 83,85 +1,26% 1,40% 3.420.600
28/02/2017 82,82 83,48 82,58 82,81 -0,30% 1,09% 3.672.000
27/02/2017 82,83 83,40 82,66 83,06 +0,23% 0,89% 3.104.200
24/02/2017 82,42 83,24 82,24 82,87 +0,39% 1,21% 4.016.000
23/02/2017 81,38 82,88 81,14 82,55 +1,83% 2,14% 6.193.500
22/02/2017 80,42 81,21 80,33 81,07 +0,88% 1,09% 3.468.800
21/02/2017 80,17 80,87 80,11 80,36 -0,04% 0,95% 3.178.800
17/02/2017 80,14 81,00 80,07 80,39 +0,44% 1,16% 3.111.100